EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials

Serena M Vilasi iD, Craig L Slingluff iD

Vaccines · 16.02.2025 · 13 (2) · 194

DOI: 10.3390/vaccines13020194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 16.02.2025. Verfasst von Serena M Vilasi und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Virginia, Charlottesville, VA 22903, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH/NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Little is known about the impact of patient age and biological sex on immune responses to melanoma vaccines, especially CD4+ T cell immune responses to peptides presented by Class II MHC molecules.

Methods

We assessed the impact of age and sex on CD4+ T cell and antibody responses to a mixture of six melanoma helper peptides (6MHP) and on CD8+ T cell responses when vaccinating with 12 class I MHC-restricted melanoma peptides (12MP) plus either 6MHP or a tetanus helper T cell peptide (Tet). We hypothesized that immune responses would be greater in men and in younger patients.

Results

We found differences in immune response by sex, but they favored female patients and were only evident for helper T cell responses to Tet with a weak trend to higher T cell responses to 12MP in female patients vaccinated with 12MP + Tet. The age-based differences favored younger patients but only for immune response to 12MP when inoculated with 12MP + Tet.

Conclusions

These findings reinforce the importance of assessing sex- and age-based differences in immune responses to cancer vaccines and other immune therapies. There is also a need to understand the reasons for such differences.

Schlagwörter

Stichwörter der Autor:innen

T cell responsemelanoma vaccinepatient agepatient sexpeptide vaccine

Autor:innen und Institutionen

  • School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
  • Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA 22903, USA.

ORCID-Profile: Serena M Vilasi, Craig L Slingluff

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH/NIAID
  • NIH/NCI R01
  • NIH/NCI R21
  • NIH/NCI P30
  • NIH/NIAID T35
  • Alice and Bill Goodwin and the Commonwealth Foundation for Cancer Research

Zitieren

APA

Vilasi, S. M., & Slingluff, C. L. (2025). Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials. Vaccines, 13(2), 194. https://doi.org/10.3390/vaccines13020194

Vancouver

Vilasi SM, Slingluff CL. Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials. Vaccines. 2025;13(2):194. doi:10.3390/vaccines13020194

BibTeX
@article{Vilasi2025,
  author = {Vilasi, Serena M and Slingluff, Craig L},
  title = {Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {2},
  pages = {194},
  doi = {10.3390/vaccines13020194}
}
Kostenlos starten →